Sodium glucose cotransporter‐2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function
Autor: | Chun-Li Wang, Pao-Hsien Chu, Chien-Ying Huang, Tzyy-Jer Hsu, Yi-Wei Kao, Yi-Hsin Chan |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Heart failure Systolic function Dipeptidyl peptidase-4 inhibitor 030204 cardiovascular system & hematology Ventricular Function Left Cohort Studies 03 medical and health sciences 0302 clinical medicine Internal medicine Type 2 diabetes mellitus medicine Dipeptidyl peptidase‐4 inhibitor Humans Diseases of the circulatory (Cardiovascular) system In patient 030212 general & internal medicine Sodium-Glucose Cotransporter 2 Inhibitor cardiovascular diseases Sodium-Glucose Transporter 2 Inhibitors Ejection fraction business.industry Type 2 Diabetes Mellitus medicine.disease Treatment Outcome Diabetes Mellitus Type 2 Echocardiography RC666-701 Cardiology cardiovascular system Cardiology and Cardiovascular Medicine business Sodium glucose cotransporter‐2 inhibitor medicine.drug Cohort study circulatory and respiratory physiology |
Zdroj: | ESC Heart Failure, Vol 7, Iss 5, Pp 2784-2796 (2020) |
ISSN: | 2055-5822 |
Popis: | Aims Recent studies indicated that sodium glucose cotransporter‐2 inhibitors (SGLT2i) reduced heart failure hospitalization in patients with type 2 diabetes mellitus (T2DM). However, whether SGTL2i can improve left ventricular (LV) systolic and diastolic function remained unclear. This study aimed to compare the change in echocardiographic parameters in T2DM patients receiving SGLT2i with a different baseline LV ejection fraction (LVEF). The change in echocardiographic parameters was also compared between T2DM patients treated with SGLT2i and those treated with dipeptidyl peptidase‐4 inhibitor (DPP4i). Methods and results This multicentre cohort study consecutively enrolled 665, 119, and 132 T2DM patients treated with SGLT2i with a preserved (≥50%), moderately reduced (40–50%), and reduced baseline LVEF ( |
Databáze: | OpenAIRE |
Externí odkaz: |